Microbot Showcases LIBERTY Robot at Surgical Innovation Summit

Microbot Medical ( (MBOT) ) has shared an announcement.

Microbot Medical Inc. is a commercial-stage medical device company specializing in robotic solutions for endovascular procedures, led by its FDA-cleared LIBERTY Endovascular Robotic System. The company targets improved precision, safety and accessibility in vascular care, promoting a single-use, remotely operated platform that aims to reduce barriers to adoption of surgical robotics.

On February 19, 2026, Microbot Medical reported that CEO Harel Gadot would be a featured panelist at The Surgical Disruptive Technology Summit, part of SAGES NBT Innovation Weekend in Houston from February 19-21, 2026. His participation on an AI and robotics endovascular panel is intended to showcase LIBERTY’s capabilities and support broader market visibility ahead of a planned full market release at the Society of Interventional Radiology conference in April 2026.

The company is using this high-profile industry forum to position LIBERTY as a new class of surgical robotics focused on minimally invasive and remote endovascular interventions. Management highlights that LIBERTY’s single-use, compact format and precision navigation are designed to remove historical barriers to robotic adoption, potentially expanding access to advanced care and deepening adoption across a wider base of health systems and patients.

The most recent analyst rating on (MBOT) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular interventions, targeting greater precision, efficiency and safety in vascular care.

Backed by a broad intellectual property portfolio, the company is positioning LIBERTY as a new class of surgical robotics that lowers traditional adoption barriers. Its market focus includes expanding access to robotic-assisted endovascular care across a wider range of health systems and patients globally, leveraging minimally invasive and remote capabilities to improve clinical outcomes.

On February 19, 2026, Microbot Medical announced that CEO, President and Chairman Harel Gadot would serve as a featured panelist at The Surgical Disruptive Technology Summit during SAGES NBT Innovation Weekend in Houston, held February 19-21, 2026. The conference brings together global robotic leaders to discuss next-decade surgical advancements, with a special emphasis on minimally and less invasive endovascular interventions.

Gadot is participating in a dedicated panel on Endovascular Therapeutics: AI and Robotics, where he is expected to highlight the unique features of the LIBERTY system and its role in defining a new category of surgical robotics. The appearance underscores Microbot’s effort to increase market visibility for LIBERTY, which recently entered limited market release in late 2025 and is slated for full market launch at the Society of Interventional Radiology conference in April 2026.

The company emphasizes LIBERTY’s single-use, compact, remotely operated design as a way to overcome longstanding hurdles to wider surgical robotics adoption. By enabling precise vascular navigation while aiming to reduce radiation exposure and physical strain, LIBERTY is intended to broaden access to advanced endovascular robotics and support deeper clinical acceptance across the vascular care continuum.

Average Trading Volume: 2,288,869

Technical Sentiment Signal: Sell

Current Market Cap: $142.4M

For an in-depth examination of MBOT stock, go to TipRanks’ Overview page.